Mifepristone is not recommended to patients with renal failure, hepatic failure, and malnutrition. The administration of the MTP Kit must be under the supervision of a certified gynecologist.
Currently, there is no data on the safety and effectiveness of MTP kits in women with chronic diseases such as heart disease, hypertension, liver dysfunction, respiratory or kidney disease, insulin-dependent diabetes, severe anemia, or heavy smoking. Women above 35 years of age who smoke should be treated with great caution.
Patients should be advised of the MTP Kit administration and its effects. They must understand the necessity of the treatment and the importance of the second visit.
Another pregnancy may occur following the termination of pregnancy. So, contraception must be initiated soon after using the MTP Kit before the woman resumes sexual intercourse. Please note that clinical examination is imperative to confirm the complete pregnancy termination after the treatment. In some women, a decrease in hemoglobin concentration, hematocrit, and red blood cell count may occur for those who bleed heavily.
Comments
Post a Comment